How does ibogaine interact with opioid receptors?

Ibogaine's Interaction with Opioid Receptors

Ibogaine acts as a kappa-opioid receptor agonist and mu-opioid receptor agonist with moderate affinity, while its active metabolite noribogaine demonstrates even higher affinity for all three opioid receptor subtypes (kappa, mu, and delta). 1, 2, 3

Receptor Binding Profile

Ibogaine's opioid receptor interactions are complex and involve multiple binding sites:

Kappa-Opioid Receptors

• Highest affinity: Ki = 3.77 μM for ibogaine 3
• Noribogaine shows stronger binding: Ki = 0.96 μM 3
• This kappa-agonist action contributes significantly to ibogaine's effects on reducing opioid and stimulant self-administration 1, 2

Mu-Opioid Receptors

• Dual affinity states: Ibogaine recognizes different agonist affinity states of the mu receptor, with Ki values of approximately 130 nM (high affinity) and 4 μM (low affinity) 4
• Noribogaine is more potent: Ki = 2.66 μM compared to ibogaine's 11.04 μM in standard assays 3
• The high-affinity mu-agonist action (130 nM) explains ibogaine's antinociceptive effects and its ability to reduce opioid withdrawal symptoms 4

Delta-Opioid Receptors

• Minimal affinity for ibogaine: Ki > 100 μM 3
• Noribogaine shows moderate affinity: Ki = 24.72 μM 3

Functional Mechanisms Beyond Simple Agonism

The opioid receptor interactions are only part of ibogaine's mechanism. Ibogaine simultaneously acts as an NMDA receptor antagonist, and the combination of kappa-opioid agonism plus NMDA antagonism appears critical for its anti-addictive effects 1, 2. Studies demonstrate that administering both a kappa-antagonist (norbinaltorphimine) and NMDA agonist together can partially reverse ibogaine's effects on morphine self-administration and morphine-induced locomotor stimulation 2.

Metabolite Contribution

Noribogaine, ibogaine's primary metabolite, demonstrates 3-4 times higher affinity for opioid receptors than the parent compound 3. This is clinically significant because:

• Ibogaine is sequestered in fat tissue and slowly released 1, 5
• Conversion to noribogaine provides sustained opioid receptor activity
• The long-term effects observed clinically (lasting days to weeks) likely result from this slow-release mechanism and active metabolite formation 1, 5

Dopaminergic Effects Mediated by Opioid Actions

Ibogaine's opioid receptor activity translates into specific dopaminergic effects:

• Acutely decreases dopamine in the nucleus accumbens 1, 5
• Blocks morphine-induced dopamine release when given 19 hours prior 1
• Blocks nicotine-induced dopamine release 1
• These effects on the mesolimbic reward pathway contribute to reduced drug-seeking behavior

Clinical Implications for Myelination

Recent evidence shows that ibogaine administration following repeated morphine exposure significantly upregulates myelination markers CNP and MBP in white matter, with effects becoming highly significant at 72 hours post-administration 6. This suggests opioid receptor modulation may trigger remyelination processes relevant to treating substance use disorders.

Important Caveats

While ibogaine shows opioid receptor activity, it should not be viewed as a replacement for evidence-based medications for opioid use disorder (methadone, buprenorphine) 7. The risk profile includes:

• Cardiac effects (bradycardia, QTc prolongation at high doses) 5
• Cerebellar neurotoxicity at doses ≥100 mg/kg 5
• Whole-body tremors 5
• Lack of FDA approval and limited safety data in controlled settings 7

Discontinuing proven mortality-reducing MOUD in favor of ibogaine could increase overdose risk 7, making any clinical application premature until rigorous safety and efficacy trials are completed.